A carregar...
Tolvaptan is effective in treating patients with refractory ascites due to cirrhosis
The treatment of refractory ascites due to cirrhosis is a clinical challenge for hepatologists. Tolvaptan, a novel aquaporin modulator, was made available in Japan in 2013 for the treatment of patients with refractory ascites due to cirrhosis. Despite the potential of this drug, few reports are avai...
Na minha lista:
| Publicado no: | Biomed Rep |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5727763/ https://ncbi.nlm.nih.gov/pubmed/29250327 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/br.2017.1005 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|